Zantac / Ranitidine (NDMA Cancer) Attorney in New York, New York

Zantac Litigation in New York City

New York City's state courts apply the Frye standard for novel scientific expert testimony — asking whether the expert's methodology is generally accepted in the relevant scientific community. This standard is similar to Delaware's and potentially more permissive for Zantac causation experts than the Daubert standard used in federal court and states like Texas and Florida. New York's 3-year SOL under CPLR § 214-c for toxic exposure cases provides additional time for claimants. The federal Zantac MDL (No. 2924, S.D. Florida) was largely dismissed in 2022 after Judge Robin Rosenberg excluded plaintiffs' causation experts under Daubert. However, the Delaware Superior Court under Judge Vivian Medinilla continues to actively hear Zantac cases and has allowed causation experts to proceed. Defendants Sanofi, Boehringer Ingelheim, GSK, and Pfizer are all actively litigating in Delaware. For most claimants, filing in Delaware Superior Court through national plaintiffs' counsel is now the primary path forward.

Cancer Screening and Documentation for NYC Zantac Claimants

New York City Zantac claimants should compile pharmacy records (CVS, Walgreens, Duane Reade, and independent pharmacies all stocked ranitidine OTC and Rx), oncology records documenting cancer diagnosis and staging, and any documentation of Zantac purchase history. New York's large plaintiffs' bar includes firms with Zantac coordination experience. Claimants may file in New York County Supreme Court or coordinate filing in Delaware Superior Court depending on case strategy.